In last trading session, Cartesian Therapeutics Inc (NASDAQ:RNAC) saw 68502.0 shares changing hands with its beta currently measuring 0.59. Company’s recent per share price level of $17.91 trading at -$0.74 or -3.97% at ring of the bell on the day assigns it a market valuation of $455.18M. That closing price of RNAC’s stock is at a discount of -137.86% from its 52-week high price of $42.60 and is indicating a premium of 34.9% from its 52-week low price of $11.66. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.16 million shares which gives us an average trading volume of 103.60K if we extend that period to 3-months.
Cartesian Therapeutics Inc (NASDAQ:RNAC) trade information
Upright in the red during last session for losing -3.97%, in the last five days RNAC remained trading in the green while hitting it’s week-highest on Monday, 11/25/24 when the stock touched $17.91 price level, adding 9.55% to its value on the day. Cartesian Therapeutics Inc’s shares saw a change of -13.40% in year-to-date performance and have moved 5.73% in past 5-day. Cartesian Therapeutics Inc (NASDAQ:RNAC) showed a performance of -19.87% in past 30-days. Number of shares sold short was 1.86 million shares which calculate 18.67 days to cover the short interests.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Wall Street analysts have assigned a consensus price target of 43 to the stock, which implies a rise of 58.35% to its current value. Analysts have been projecting 40 as a low price target for the stock while placing it at a high target of 45. It follows that stock’s current price would drop -123.34% in reaching the projected high whereas dropping to the targeted low would mean a loss of -123.34% for stock’s current value.
Cartesian Therapeutics Inc (RNAC) estimates and forecasts
Statistics highlight that Cartesian Therapeutics Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -43.03% of value to its shares in past 6 months, showing an annual growth rate of 52.01% while that of industry is 17.60. Apart from that, the company came raising its revenue forecast for fiscal year 2024. This year revenue growth is estimated to rise 53.13% from the last financial year’s standing.
2 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 150k for the same. And 1 analysts are in estimates of company making revenue of 5M in the next quarter. Company posted 26M and 5.84M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 10.69% during past 5 years.
